A M55V Polymorphism in the SUMO4 Gene is Associated with a Reduced Prevalence of Diabetic Retinopathy in Patients with Type 1 Diabetes

Aims: Methods: Results: Conclusions:

[1]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[2]  M. Hsieh,et al.  SUMO4 M55V Variant Is Associated With Diabetic Nephropathy in Type 2 Diabetes , 2007, Diabetes.

[3]  Paul Mitchell,et al.  The eye in hypertension , 2007, The Lancet.

[4]  T. Ogihara,et al.  Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes. , 2005, Diabetes.

[5]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[6]  A. Aljada,et al.  Contemporary Reviews in Cardiovascular Medicine Metabolic Syndrome A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation , 2022 .

[7]  K. Bohren,et al.  A M55V Polymorphism in a Novel SUMO Gene (SUMO-4) Differentially Activates Heat Shock Transcription Factors and Is Associated with Susceptibility to Type I Diabetes Mellitus* , 2004, Journal of Biological Chemistry.

[8]  M. Matunis,et al.  SUMO Modification of Heterogeneous Nuclear Ribonucleoproteins , 2004, Molecular and Cellular Biology.

[9]  J. Schneider,et al.  A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[10]  A. Hamann,et al.  New treatments for diabetic neuropathy: Pathogenetically oriented treatment , 2003, Current diabetes reports.

[11]  H. Hammes,et al.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.

[12]  Timothy S Kern,et al.  Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. , 2002, Diabetes.

[13]  Factors in Development of Diabetic Neuropathy: Baseline Analysis of Neuropathy in Feasibility Phase of Diabetes Control and Complications Trial (DCCT) , 1988, Diabetes.

[14]  Yan Zhang,et al.  A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. , 2004, Nature genetics.

[15]  R. Gaynor,et al.  IkappaB kinases: key regulators of the NF-kappaB pathway. , 2004, Trends in biochemical sciences.

[16]  Csaba Szabó,et al.  Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. , 2004, Diabetes.

[17]  S. Schiekofer,et al.  The role of oxidative stress and NF‐κB activation in late diabetic complications , 1999, BioFactors.

[18]  L. Vuillard,et al.  Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[19]  B. Isermann,et al.  Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. , 1999, Diabetologia.

[20]  T. Gilmore,et al.  Control of apoptosis by Rel/NF-kappaB transcription factors. , 1999, Oncogene.